Aeolus publishes data from mustard gas skin treatment study

Aeolus Pharmaceuticals, Inc., announced the publication on Wednesday of data from animal model studies that demonstrated the efficacy of its broad-spectrum catalytic antioxidant in treating skin lesions from CEES, a sulfur mustard gas analog.

The studies found that AEOL 10150 reversed more than 50 percent of CEES-induced skin bi-fold and epidermal thickness, DNA oxidation, and myeloperoxidase activity in mouse skin. The antioxidant also attenuated CEES-induced DNA damage and significantly ameliorated oxidative stress in mouse and human cells.

"Our study demonstrates the potential of AEOL 10150 in treating skin lesions caused from exposure to vesicating agents, which can be further optimized and developed as a medical countermeasure against vesicant exposure-related skin effects," Rajesh Agarwal, a professor at the Department of Pharmaceutical Sciences at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, said.

AEOL 10150 is designed to neutralize reactive oxygen and nitrogen species, which reduces oxidative stress, inflammation and tissue damage resulting from exposure to radiation and chemical agents. The National Institutes of Health's Countermeasures Against Chemical Threats (CounterACT) program is funding the development of AEOL 10150 as a treatment for chemical vesicant and nerve agent exposure. The Biomedical Advanced Research and Development Authority awarded Aeolus a five-year contract to develop AEOL 10150 as a treatment for the lung syndrome of acute radiation syndrome.

"The data published in this paper further supports the testing and optimization of AEOL 10150 in skin injury models with topical nitrogen mustard and sulfur mustard exposure," John McManus, the CEO of Aeolus, said. "These studies open up a new potential development pathway for AEOL 10150 in the treatment of skin injury from chemical vesicants. AEOL 10150 continues to demonstrate effectiveness as (a medical countermeasure) against radiological and chemical injury and represents a potential solution to multiple threats. We are grateful to CounterACT for their support of these studies and to Dr. Agarwal and his team for their research efforts."

Aeolus is a biotechnology company focused on developing compounds to protect against chemical and radiological threats.

Organizations in this Story

Aeolus Pharmaceuticals

Want to get notified whenever we write about Aeolus Pharmaceuticals ?
Next time we write about Aeolus Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.